TY - JOUR
T1 - Curcumin-sulfobutyl-ether beta cyclodextrin inclusion complex
T2 - preparation, spectral characterization, molecular modeling, and antimicrobial activity
AU - Sravani, Anne Boyina
AU - Shenoy K, Mangala
AU - Chandrika, Baby
AU - Kumar B, Harish
AU - Kini, Suvarna G.
AU - Pai K, Sreedhara Ranganatha
AU - Lewis, Shaila A.
N1 - Funding Information:
The authors are grateful to Dr Avinash Kumar, Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, for his assistance in carrying out computational studies. The authors are also grateful to the Indian Council of Medical Research (ICMR), Government of India for providing Senior Research Fellowship (SRF) to Anne Boyina Sravani [File No. 3/2/2/15/2020/NCD-III] and Manipal College of Pharmaceutical Sciences (MCOPS) and Manipal Academy of Higher Education (MAHE), Manipal for carrying out the research work. The authors are thankful to the Central Instrumentation Facility (CIF, Manipal) for providing the characterization facility. The authors would like to acknowledge the Manipal-Schrödinger Centre for Molecular Simulations, MCOPS, Manipal for providing facilities to conduct docking studies.
Publisher Copyright:
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Urinary tract infections (UTIs) caused by Gram-negative bacteria E. coli is responsible for 80–90% of uncomplicated cases in women. The increased prevalence of antibiotic resistance has made the management of UTIs more challenging. Plant-derived compounds have long been used to treat various diseases, and constitute an alternative to antibiotic resistance. Curcumin (CUR), a naturally occurring polyphenolic phytoconstituent obtained from Curcuma longa is endowed with diverse medicinal properties. The present study aims to form a complex of CUR with Sulfobutyl ether-β-cyclodextrin (SBEβCD) to overcome the poor solubility and bioavailability of CUR and to evaluate the antimicrobial activity of CUR-SBEβCD. Phase solubility studies and spectral characterization showed the entrapment of CUR in the SBEβCD cavity. In silico docking studies performed to investigate the complexation process of CUR with SBEβCD, revealed that the methoxy group and OH group of CUR interacted with SBEβCD. The cytotoxicity and HET-CAM assays confirmed that CUR-SBEβCD was non-irritant. The prepared complex investigated with the disc diffusion method showed antimicrobial activity with a zone of inhibition (ZOI) of 13 mm against Escherichia coli (E. coli) and 11.5 mm against Staphylococcus aureus (S. aureus) whereas CUR alone did not show any ZOI. It can be concluded that prepared CUR-SBEβCD demonstrated superior antimicrobial activity and therefore can be a promising alternative for the treatment of UTIs. Communicated by Ramaswamy H. Sarma.
AB - Urinary tract infections (UTIs) caused by Gram-negative bacteria E. coli is responsible for 80–90% of uncomplicated cases in women. The increased prevalence of antibiotic resistance has made the management of UTIs more challenging. Plant-derived compounds have long been used to treat various diseases, and constitute an alternative to antibiotic resistance. Curcumin (CUR), a naturally occurring polyphenolic phytoconstituent obtained from Curcuma longa is endowed with diverse medicinal properties. The present study aims to form a complex of CUR with Sulfobutyl ether-β-cyclodextrin (SBEβCD) to overcome the poor solubility and bioavailability of CUR and to evaluate the antimicrobial activity of CUR-SBEβCD. Phase solubility studies and spectral characterization showed the entrapment of CUR in the SBEβCD cavity. In silico docking studies performed to investigate the complexation process of CUR with SBEβCD, revealed that the methoxy group and OH group of CUR interacted with SBEβCD. The cytotoxicity and HET-CAM assays confirmed that CUR-SBEβCD was non-irritant. The prepared complex investigated with the disc diffusion method showed antimicrobial activity with a zone of inhibition (ZOI) of 13 mm against Escherichia coli (E. coli) and 11.5 mm against Staphylococcus aureus (S. aureus) whereas CUR alone did not show any ZOI. It can be concluded that prepared CUR-SBEβCD demonstrated superior antimicrobial activity and therefore can be a promising alternative for the treatment of UTIs. Communicated by Ramaswamy H. Sarma.
UR - http://www.scopus.com/inward/record.url?scp=85170695587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85170695587&partnerID=8YFLogxK
U2 - 10.1080/07391102.2023.2254409
DO - 10.1080/07391102.2023.2254409
M3 - Article
C2 - 37695658
AN - SCOPUS:85170695587
SN - 0739-1102
VL - 42
SP - 9977
EP - 9992
JO - Journal of Biomolecular Structure and Dynamics
JF - Journal of Biomolecular Structure and Dynamics
IS - 19
ER -